Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study

Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treatment. The aim of this study is to assess the real-life outcomes of use of apremilast in patients with psoriasis in everyday clinical practice. A total of 159 adult patients (90 males) with plaque psor...

Full description

Saved in:
Bibliographic Details
Published in:Acta dermato-venereologica 2021-09, Vol.101 (9), p.adv00545-adv00545
Main Authors: Malara, G, Politi, C, Trifirò, C, Verduci, C, D'Arrigo, G, Testa, A, Tripepi, G
Format: Article
Language:English
Subjects:
apremilast
Clinical Report
obesity
psoriasis
psoriatic arthritis
retention rate
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treatment. The aim of this study is to assess the real-life outcomes of use of apremilast in patients with psoriasis in everyday clinical practice. A total of 159 adult patients (90 males) with plaque psoriasis were included in the study. Fifty of the patients (31%) had psoriatic arthritis. All patients started apremilast at the time of enrolment. There was a marked improvement in Psoriasis Area and Severity Index, body surface area and Dermatology Life Quality Index scores across the follow-up period (12 months). The improvements in these scores were also consistent when the patients were stratified according to increasing body mass index. Only 10.6% of the patients discontinued apremilast, because of no response. In conclusion, apremilast is an effective and safe treatment in patients with psoriasis, and its effect is not influenced by body mass index.
ISSN:1651-2057
0001-5555
1651-2057
DOI:10.2340/00015555-3846